Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

ide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH and the Company began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is actively pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

This news release contains forward-looking statements, including statements related to potential benefits and commercial potential for Soliris, and interest about Soliris in the patient, physician and payor communities. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
(Date:8/22/2014)... 22, 2014  - ... Today Lincor announced general availability of MediaLINC ... delivers a range of education, entertainment and clinical content ... (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor ... care patient engagement to bedside smart devices, " comments ...
(Date:8/22/2014)... , Aug. 22, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... that William E. Saxelby , its President and ... and Chief Executive Officer and as a member of ... 2014.  He will be replaced on an interim basis ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Landauer, Inc. Announces Executive Management Change 2
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and retailer, ... gowns . In addition to this, the company’s sales ... provided with low shipping fees. , He says ... wedding gowns. In our online store, there are thousands ... from. What’s more, all of them are extremely beautiful. ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Mi40x , ... university-proven research to show people how they can use a ... in only a matter of weeks has caught the attention ... Pakulski is one of the most well-known bodybuilders in the ... body he has today, that in itself is a testament ...
(Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
(Date:8/22/2014)... 2014 Mueller Sports Medicine is excited ... exciting new product that provides non-drug instant relief for ... while you heal. The package includes 7 days of ... technology – it is not kinesiology tape. It’s made ... System for Plantar Fasciitis is a breakthrough in ...
Breaking Medicine News(10 mins):Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... , , ... ... ... , , ...
... ... their use of mobile technology and their participation in online physician networking. Approximately ... most popular handheld device or smartphone is the Apple iPhone, with 31% of respondents ... ...
... Heavy screen time in youth means trouble by mid-40s, despite activity ... who watch more television in their 20s and 30s are more ... reach their mid-40s than people who spent less time in front ... worrisome enough for many, the worse news is that you can,t ...
... ... ... , , ... WHITE ...
... ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Statement from Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, On the Therapy Cap Coalition Press Conference 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 2Health News:SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone 3Health News:You Can't Exercise Away TV's Toll on the Heart 2Health News:You Can't Exercise Away TV's Toll on the Heart 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 2Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 3Health News:March of Dimes President Dr. Jennifer L. Howse Wins Prestigious Humanitarian Award 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 2Health News:Kaiser Permanente Completes Electronic Health Record Implementation 3Health News:Kaiser Permanente Completes Electronic Health Record Implementation 4Health News:Kaiser Permanente Completes Electronic Health Record Implementation 5Health News:Kaiser Permanente Completes Electronic Health Record Implementation 6Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 2Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 3Health News:Seattle Sutton's Healthy Eating Sponsoring The Biggest Loser Chicago Casting Call 4
... Test is a one step urine ... occured. This test can show a ... (FSH), which indicates whether menopause has ... use and in a few minutes, ...
... The female Fertell test is an easy to ... measures ovarian reserve by means of determining the ... in-stream urine sample. The test is performed two ... of the menstrual cycle) and is similar in ...
... System brings a wealth of benefits to healthcare ... ability to measure a complete lipid profile and ... it all in 5 minutes per test cassette ... quick product demo, click here ., ,The ...
The Lifestream Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program. At a later date, you can purchase the other components...
Medicine Products: